153 related articles for article (PubMed ID: 37229833)
41. [Establish a predictive modeling under antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B].
Liu GW; Tang KC; Li Q; Lu W
Zhonghua Gan Zang Bing Za Zhi; 2018 Sep; 26(9):641-645. PubMed ID: 30481858
[No Abstract] [Full Text] [Related]
42. The premise of capsid assembly modulators towards eliminating HBV persistence.
Bassit L; Amblard F; Patel D; Biteau N; Chen Z; Kasthuri M; Zhou S; Schinazi RF
Expert Opin Drug Discov; 2023; 18(9):1031-1041. PubMed ID: 37477111
[TBL] [Abstract][Full Text] [Related]
43. Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment.
Hao R; Xiang K; Peng Y; Hou J; Sun J; Li Y; Su M; Yan L; Zhuang H; Li T
Infect Genet Evol; 2015 Jul; 33():261-8. PubMed ID: 25976382
[TBL] [Abstract][Full Text] [Related]
44. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
[TBL] [Abstract][Full Text] [Related]
45. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
46. Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection.
Hu Y; Sun F; Yuan Q; Du J; Hu L; Gu Z; Zhou Q; Du X; He S; Sun Y; Wang Q; Fan L; Wang L; Qin S; Chen S; Li J; Wu W; Mao J; Zhou Y; Zhou Q; Zhang G; Ding CZ
Bioorg Med Chem Lett; 2022 Nov; 75():128977. PubMed ID: 36089112
[TBL] [Abstract][Full Text] [Related]
47. Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection.
Yuen MF; Gane EJ; Kim DJ; Weilert F; Yuen Chan HL; Lalezari J; Hwang SG; Nguyen T; Flores O; Hartman G; Liaw S; Lenz O; Kakuda TN; Talloen W; Schwabe C; Klumpp K; Brown N
Gastroenterology; 2019 Apr; 156(5):1392-1403.e7. PubMed ID: 30625297
[TBL] [Abstract][Full Text] [Related]
48. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.
Chi XM; Wang XM; Wang ZF; Wu RH; Gao XZ; Xu HQ; Ding YH; Niu JQ
World J Gastroenterol; 2021 Oct; 27(40):6927-6938. PubMed ID: 34790015
[TBL] [Abstract][Full Text] [Related]
49. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
[TBL] [Abstract][Full Text] [Related]
50. [Establishment of an HBV chronic hepatitis B infection mouse model by vivo transduction of HBV cccDNA].
Zhao T; Li X; Yin W; Cai X; Zhang W; Chen F; Lai G; Huang A
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):260-5. PubMed ID: 25173223
[TBL] [Abstract][Full Text] [Related]
51. Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.
Burdette D; Hyrina A; Song Z; Beran RK; Cheung T; Gilmore S; Kobayashi T; Li L; Liu Y; Niedziela-Majka A; Medley J; Mehra U; Morganelli P; Novikov N; Niu C; Tam D; Tang J; Wang J; Yue Q; Fletcher SP; Holdorf MM; Delaney WE; Feierbach B; Lazerwith S
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0134822. PubMed ID: 36519892
[TBL] [Abstract][Full Text] [Related]
52. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
53. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference
Cornberg M; Lok AS; Terrault NA; Zoulim F;
J Hepatol; 2020 Mar; 72(3):539-557. PubMed ID: 31730789
[TBL] [Abstract][Full Text] [Related]
54. [A randomized controlled study on factors influencing the curative effect of sequential combined interferon and lamivudine therapy in children with immune-tolerant phase chronic hepatitis B].
Zhu SS; Dong Y; Zhang HF; Wang LM; Xu ZQ; Zhang M; Gan Y; Chen DW; Wang FC; Yan JG; Zhao P
Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):604-609. PubMed ID: 31594077
[No Abstract] [Full Text] [Related]
55. Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgRNA has limited impact.
Malmström S; Larsson SB; Hannoun C; Lindh M
PLoS One; 2012; 7(7):e36349. PubMed ID: 22911677
[TBL] [Abstract][Full Text] [Related]
56. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
[TBL] [Abstract][Full Text] [Related]
57. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
[TBL] [Abstract][Full Text] [Related]
58. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
[TBL] [Abstract][Full Text] [Related]
59. HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.
Yang S; Xing H; Wang Y; Hou J; Luo D; Xie Q; Ning Q; Ren H; Ding H; Sheng J; Wei L; Chen S; Fan X; Huang W; Pan C; Gao Z; Zhang J; Zhou B; Chen G; Wan M; Tang H; Wang G; Yang Y; Xu D; Dong P; Wang Q; Wang J; Bognar FA; Xu D; Cheng J
Virol J; 2016 Oct; 13(1):180. PubMed ID: 27793166
[TBL] [Abstract][Full Text] [Related]
60. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
